TRex Bio, Inc. TRXB
TRex Bio, Inc. (Nasdaq: TRXB) is an immunology/inflammation drug developer. Its lead program, TRB-061, is in Phase 1 for Moderate-to-severe atopic dermatitis (also exploring alopecia areata and other autoimmune and inflammatory diseases). Its next catalyst on record is TRB-051 (Lilly-sponsored collaboration program): Lilly intends to start Phase 2a trial in lupus with cutaneous involvement (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: TRB-051 (Lilly-sponsored collaboration program) — Lilly intends to start Phase 2a trial in lupus with cutaneous involvement (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TRB-061 (TNFR2 agonist Fc-fusion protein) | Atopic dermatitis; alopecia areata under exploration | protein/peptide | Phase 1 |
| TRB-071 (CD30 agonist monoclonal antibody) | Inflammatory bowel disease | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.